

Resource Summary Report

Generated by [SPARC SAWG](#) on Sep 4, 2026

DNMT3A-dCas9

RRID:Addgene_100090

Type: Plasmid

Proper Citation

RRID:Addgene_100090

Plasmid Information

URL: <http://www.addgene.org/100090>

Proper Citation: RRID:Addgene_100090

Insert Name: DNMT3A

Organism: Homo sapiens

Bacterial Resistance: Ampicillin

Defining Citation: [PMID:28973434](#)

Vector Backbone Description: Backbone Marker:ThermoFisher; Backbone Size:5407; Vector Backbone:pcDNA3.3-TOPO; Vector Types:Mammalian Expression, CRISPR; Bacterial Resistance:Ampicillin

Plasmid Name: DNMT3A-dCas9

Relevant Mutation: includes aa 602-912

Record Creation Time: 20220422T221446+0000

Record Last Update: 20260902T040917+0000

Ratings and Alerts

No rating or validation information has been found for DNMT3A-dCas9.

No alerts have been found for DNMT3A-dCas9.

Data and Source Information

Source: [Addgene](#)

Usage and Citation Metrics

We found 7 mentions in open access literature.

Listed below are recent publications. The full list is available at [SPARC SAWG](#) .

Hua Y, et al. (2025) Targeting SLC7A11-mediated cysteine metabolism for the treatment of trastuzumab-resistant HER2-positive breast cancer. *eLife*, 14.

Rallabandi HR, et al. (2025) Defining Mechanistic Links Between the Non-Coding Variant rs17673553 in CLEC16A and Lupus Susceptibility. *International journal of molecular sciences*, 26(1).

Hinrichs AK, et al. (2024) Dual-Luciferase Reporter Assay for Prescreening CRISPR (d)Cas9-Mediated Epigenetic Editing on a Plant Promoter Using Human Cells. *Methods in molecular biology (Clifton, N.J.)*, 2788, 273.

Woods ML, et al. (2022) Epigenetically silenced apoptosis-associated tyrosine kinase (AATK) facilitates a decreased expression of Cyclin D1 and WEE1, phosphorylates TP53 and reduces cell proliferation in a kinase-dependent manner. *Cancer gene therapy*, 29(12), 1975.

O'Geen H, et al. (2022) Determinants of heritable gene silencing for KRAB-dCas9 + DNMT3 and Ezh2-dCas9 + DNMT3 hit-and-run epigenome editing. *Nucleic acids research*, 50(6), 3239.

O'Geen H, et al. (2019) Ezh2-dCas9 and KRAB-dCas9 enable engineering of epigenetic memory in a context-dependent manner. *Epigenetics & chromatin*, 12(1), 26.

Deuschmeyer V, et al. (2019) Epigenetic therapy of novel tumour suppressor ZAR1 and its cancer biomarker function. *Clinical epigenetics*, 11(1), 182.